<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771914</url>
  </required_header>
  <id_info>
    <org_study_id>Study Protocol 112421</org_study_id>
    <nct_id>NCT00771914</nct_id>
  </id_info>
  <brief_title>The Effects of Omega-3 Fatty Acids on Aspirin Resistance</brief_title>
  <official_title>The Effects of Omega-3 Fatty Acids on Aspirin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>American College of Clinical Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if omega-3 fatty acids enhance the antiplatelet
      effects of aspirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although aspirin has been a stalwart treatment in the prevention and treatment of myocardial
      infarction and stroke, it does not have its expected effects in a significant proportion of
      the population. This phenomenon has been termed &quot;aspirin resistance&quot;. Omega-3 fatty acid
      supplementation has been associated with a reduced risk of sudden cardiac death and
      myocardial infarction. The beneficial effects of omega-3s are considered to be partially due
      to their ability to prevent platelet aggregation. However, the ability of omega-3s to enhance
      the effects of aspirin in those who suffer from aspirin resistance has not been determined.
      It is known that aspirin stimulates the production of potent lipid mediators from omega-3
      fatty acids and that these mediators have powerful antiinflammatory and tissue-protective
      effects. Thus, the treatment of individuals at high risk for myocardial infarction and stroke
      with both aspirin and a pharmaceutical-grade omega-3 fatty acid medication may be a powerful
      combination in the prevention and treatment of life-threatening cardiovascular disease.

      Study Protocol: Non-smoking male and female subjects between the ages of 18 and 50 not taking
      any medications, vitamin pills, nutritional supplements, or herbal preparations were
      recruited. Subjects with a history of chronic diseases (e.g. cardiovascular, renal, hepatic,
      neurodegenerative, neoplastic, metabolic {diabetes}, hypertension; based on screening medical
      history, a complete blood count, and comprehensive metabolic profile), or allergic reactions
      to aspirin, fish, fish oils, or non-steroidal anti-inflammatory drugs were excluded. Other
      exclusions included drinking more than three alcoholic beverages a day, or having any of the
      following conditions: an ulcer or bleeding in the stomach, liver or kidney disease, bleeding
      or blood clotting disorder (e.g. hemophilia), congestive heart failure, fluid retention, high
      blood pressure, gout, asthma, arthritis, or nasal polyps. This was a randomized,
      placebo-controlled, double-blinded trial with a cross-over design. Each subject served as
      his/her own control. The study involved four visits four weeks apart, all hosted in the
      University of Rochester Clinical Research Center. At each separate study visit, each subject
      received (using a randomized protocol) placebo, 81 mg aspirin, 4 g Lovaza(R)(3.4g of
      EPA+DHA), or both aspirin and Lovaza(R). Thus, each subject received each of these treatments
      individually in a random fashion over the four visits. Subjects, Center staff, and
      investigators were blinded as to which treatment was given at each visit and this ensured by
      the study pharmacist making the tablets and capsules for each treatment appear identical.
      Prior to each visit, subjects ate a standard low-fat dinner the prior evening, then fasted
      for at least 8 hours prior to arrival at the Center. Subjects were required to abstain from
      taking aspirin or non-steroidal anti-inflammatory drugs for 10 days prior to each visit and
      omega-3 fatty acids for 30 days prior to the baseline study visit, and all subsequent clinic
      visits. Visits lasted approximately 6 hours, with subjects at bedrest. A venous catheter was
      placed in a peripheral vein (saline lock, 18 gauge or larger, {no heparin used} in the
      forearm) with blood drawn, at baseline and 4 hours post-treatment, into citrated tubes at
      each visit for Platelet Function Analyzer-100 (PFA-100-Siemens, Deerfield, IL) closure time
      testing. Subjects were provided with a standard low-fat breakfast after the baseline
      phlebotomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Difference Between the Time to Clot Formation in Seconds at Baseline and After Each Treatment</measure>
    <time_frame>4 hours</time_frame>
    <description>The PFA-100 test measures platelet function as the time that it takes for a clot to form in a collagen-lined cartridge.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Increased Drug Resistance</condition>
  <arm_group>
    <arm_group_label>Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First Placebo, then 4 grams of Lovaza, then 81mg of Aspirin, then both 4 grams of Lovaza and 81 mg of Aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 81mg of Aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 4 grams of Lovaza, then 81mg of Aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 81mg tablet</description>
    <arm_group_label>Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza</arm_group_label>
    <arm_group_label>Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo</arm_group_label>
    <arm_group_label>Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin</arm_group_label>
    <arm_group_label>Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza</intervention_name>
    <description>Lovaza 4 grams</description>
    <arm_group_label>Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza</arm_group_label>
    <arm_group_label>Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo</arm_group_label>
    <arm_group_label>Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin</arm_group_label>
    <arm_group_label>Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin</arm_group_label>
    <other_name>ethyl EPA + DHA; fish oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Both Aspirin and Lovaza</intervention_name>
    <description>Lovaza 4 grams plus aspirin 81 mg</description>
    <arm_group_label>Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza</arm_group_label>
    <arm_group_label>Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo</arm_group_label>
    <arm_group_label>Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin</arm_group_label>
    <arm_group_label>Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin</arm_group_label>
    <other_name>Lovaza and aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule resembling fish oil and a tablet resembling aspirin</description>
    <arm_group_label>Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza</arm_group_label>
    <arm_group_label>Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo</arm_group_label>
    <arm_group_label>Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin</arm_group_label>
    <arm_group_label>Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to participate by providing informed consent and committing to complete the
             study. This includes adhering to the study diet.

          -  No chronic disease by history and based on a complete blood count and comprehensive
             metabolic profile.

          -  Commitment to not taking aspirin, non-steroidal anti-inflammatory medications, and to
             limit fish intake to â‰¤2 meals during the 7 days prior to each CRC study period. They
             will also need to abstain from taking a list of over-the-counter medications that
             include aspirin. For the duration of the study, they will also be asked to abstain
             from taking fish and flax seed oil supplements.

        Exclusion Criteria:

          -  Reports the presence of chronic disease (e.g. cardiovascular, renal, hepatic,
             neurodegenerative, neoplastic, metabolic {diabetes}, hypertension).

          -  Reports taking a systemic medication chronically.

          -  History of serious adverse reaction or allergy to aspirin or fish oil.

          -  Baseline platelet count &lt;100 000 or &gt;500 000, hematocrit &lt;30%, or white blood cell
             count &gt;20 000.

          -  Any abnormality from a screening CBC and complete blood count that suggests acute or
             chronic disease.

          -  Nicotine user.

          -  History of alcohol abuse

          -  Pregnancy by history or urine/serum pregnancy test

          -  History of intestinal malabsorption syndrome including gastric bypass surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C Block, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester School of Medicine and Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester School of Medicine and Dentistry</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2008</study_first_submitted>
  <study_first_submitted_qc>October 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <results_first_submitted>October 10, 2011</results_first_submitted>
  <results_first_submitted_qc>May 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 29, 2012</results_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Robert Block</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>omega 3 fatty acids</keyword>
  <keyword>Lovaza</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>aspirin resistance</keyword>
  <keyword>cardiovascular disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza</title>
          <description>First Placebo, then 4 grams of Lovaza, then 81mg of Aspirin, then both 81mg of Aspirin and 4 grams of Lovaza</description>
        </group>
        <group group_id="P2">
          <title>Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo</title>
          <description>First 81mg of Aspirin, then both 81mg of Aspirin and 4 grams of Lovaza, then 4 grams of Lovaza, then 81mg of Aspirin</description>
        </group>
        <group group_id="P3">
          <title>Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin</title>
          <description>First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 81 mg of Aspirin</description>
        </group>
        <group group_id="P4">
          <title>Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin</title>
          <description>First both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 4 grams of Lovaza, then 81mg of Aspirin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza</title>
          <description>First Placebo, then 4 grams of Lovaza, then 81 mg of aspirin, then both 81mg of Aspirin and 4 grams of Lovaza</description>
        </group>
        <group group_id="B2">
          <title>Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo</title>
          <description>First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo</description>
        </group>
        <group group_id="B3">
          <title>Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin</title>
          <description>First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then Placebo, then 81mg of Aspirin</description>
        </group>
        <group group_id="B4">
          <title>Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin</title>
          <description>First both 81mg of Aspirin and 4 grams of Lovaza, then Placebo, then 4 grams of Lovaza, then 81mg of Aspirin</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="9.7"/>
                    <measurement group_id="B2" value="32.9" spread="11.6"/>
                    <measurement group_id="B3" value="25.9" spread="3.4"/>
                    <measurement group_id="B4" value="29.3" spread="10.2"/>
                    <measurement group_id="B5" value="29.3" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Difference Between the Time to Clot Formation in Seconds at Baseline and After Each Treatment</title>
        <description>The PFA-100 test measures platelet function as the time that it takes for a clot to form in a collagen-lined cartridge.</description>
        <time_frame>4 hours</time_frame>
        <population>Each participant acted as own control since each received the intervention (placebo, aspirin, lovaza, and both aspirin and lovaza) and had these effects compared to baseline (four hour effect of each intervention).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>All participants received Placebo intervention regardless of sequence.</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>All participants received Aspirin intervention regardless of sequence.</description>
          </group>
          <group group_id="O3">
            <title>Lovaza</title>
            <description>All participants received Lovaza intervention regardless of sequence.</description>
          </group>
          <group group_id="O4">
            <title>Both Aspirin and Lovaza</title>
            <description>All participants received Aspirin and Lovaza intervention regardless of sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>the Difference Between the Time to Clot Formation in Seconds at Baseline and After Each Treatment</title>
          <description>The PFA-100 test measures platelet function as the time that it takes for a clot to form in a collagen-lined cartridge.</description>
          <population>Each participant acted as own control since each received the intervention (placebo, aspirin, lovaza, and both aspirin and lovaza) and had these effects compared to baseline (four hour effect of each intervention).</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="30"/>
                    <measurement group_id="O2" value="10.9" spread="50.23"/>
                    <measurement group_id="O3" value="-6.5" spread="63.6"/>
                    <measurement group_id="O4" value="30.5" spread="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The Wilcoxon Signed-Rank Test was used to determine significant differences between the closure time effect (clotting)in seconds from baseline compared to four hours after placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.00</p_value>
            <p_value_desc>The analyses were not adjusted for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Wilcoxon Signed-Rank Test was used to determine significant differences between the closure time effect (clotting)in seconds from Aspirin compared to Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <p_value_desc>The analyses were not adjusted for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The Wilcoxon Signed-Rank Test was used to determine significant differences between the closure time effect (clotting)in seconds from Lovaza compared to Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <p_value_desc>The analyses were not adjusted for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The Wilcoxon Signed-Rank Test was used to determine significant differences between the closure time effect (clotting)in seconds from both Aspirin and Lovaza compared to Placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>The analyses were not adjusted for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza</title>
          <description>First Placebo, then 4 grams of Lovaza, then 81 mg of aspirin, then both 81mg of Aspirin and 4 grams of Lovaza</description>
        </group>
        <group group_id="E2">
          <title>Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo</title>
          <description>First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo</description>
        </group>
        <group group_id="E3">
          <title>Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin</title>
          <description>First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then Placebo, then 81mg of Aspirin</description>
        </group>
        <group group_id="E4">
          <title>Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin</title>
          <description>First both 81mg of Aspirin and 4 grams of Lovaza, then Placebo, then 4 grams of Lovaza, then 81mg of Aspirin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.85</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Headache, nausea, lightheadness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Block, MD, MPH, FACP</name_or_title>
      <organization>University of Rochester Division of Epidemiology, Department of Community and Preventive Medicine</organization>
      <phone>585-275-3356</phone>
      <email>robert_block@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

